Metagenomi Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Asset
Metagenomi Therapeutics, Inc. (MGX) reported Increase (Decrease) in Contract with Customer, Asset of -$1.27 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2025-03-17
- Metagenomi Therapeutics, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2023-12-31 was $0.00.
- Metagenomi Therapeutics, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2023-09-30 was $0.00.
- Metagenomi Therapeutics, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2023-06-30 was $0.00.
- Metagenomi Therapeutics, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2023-03-31 was -$1.27M.
- Metagenomi Therapeutics, Inc. increase (decrease) in contract with customer, asset for fiscal 2023 was -$1.27M.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $0.00 derived: sum of 3 quarters · filed 2025-03-17 | -$1.27M 10-K · filed 2025-03-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | -$1.27M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$1.27M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$1.27M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |